Trials and registries - Managing bleeding risk in search of optimal drug-device synergy

Presentations available when logged in:

• The risk of major bleeding with novel antiplatelet agents after an acute coronary event: a comparison of ticagrelor and clopidogrel in 5,116 consec...
• Long-term ticagrelor monotherapy for 23 months following one-month DAPT after PCI in complex clinical scenarios. Pre-specified clinical subgroup an...
• Microvascular integrity and left ventricular function recovery after clopidogrel or ticagrelor administration, in patients with STEMI treated with...
• Shorter duration of triple antithrombotic therapy in atrial fibrillation patients undergoing coronary stenting
• LAA occlusion with the AMPLATZER Amulet device: primary results of the prospective global Amulet observational study